Stichting European Myeloma Network
Clinical Trials
42
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials
European Myeloma Network (EMN) Sample Project
- Conditions
- Multiple MyelomaPlasma Cell LeukemiaExtramedullary MyelomaMGUSSmoldering Multiple Myeloma
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- European Myeloma Network B.V.
- Target Recruit Count
- 6000
- Registration Number
- NCT06237803
- Locations
- 🇦🇹
KUK Linz, Linz, Austria
🇦🇹Ordensklinikum Linz, Linz, Austria
🇦🇹Medical University Vienna, Wien, Austria
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 200
- Registration Number
- NCT06189833
- Locations
- 🇦🇹
Innsbruck Medical University, Innsbruck, Austria
🇦🇹Ordensklinikum Linz, Linz, Austria
🇦🇹Clinic Ottakring, Vienna, Austria
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 50
- Registration Number
- NCT06183489
- Locations
- 🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇫🇷CHD Vendée, La Roche-sur-Yon, France
🇫🇷CHRU de Lille - Hopital Claude Huriez, Lille, France
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 750
- Registration Number
- NCT05257083
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UC San Diego Health Moores Cancer Center, San Diego, California, United States
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 1594
- Registration Number
- NCT05243797
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Phoenix, Arizona, United States
🇺🇸University of California-Davis Cancer Center, Sacramento, California, United States
🇺🇸University of California, San Diego (UCSD) Medical Center, San Diego, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next